Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarker predicts outcome for prostate cancer:

This article was originally published in Clinica

Executive Summary

The biomarker Ki-67 has emerged as a strong predictor of death from prostate cancer following radiotherapy, according to what is claimed to be the largest known study of its type. Ki-67 is involved in tumour proliferation. A team from the Fox Chase Cancer Center in Salt Lake City, Utah, performed immunohistochemical staining for Ki-67 on tissue samples from 537 patients who has undergone radiation therapy. It found that the higher the amount of Ki-67, the greater the risk the cancer would spread. The findings were reported at the this month's American Society for Therapeutic Radiology and Oncology meeting in Salt Lake City.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel